Hydroxypropyl beta-cyclodextrin compositions and methods
This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
1 . A method for treating Niemann Pick disease comprising administering to a human subject in need thereof a mixture of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, the mixture comprising beta-cyclodextrin substituted with three hydroxypropyl groups (“DS-3”), beta-cyclodextrin substituted with four hydroxypropyl groups (“DS-4”), beta-cyclodextrin substituted with five hydroxypropyl groups (“DS-5”), and beta-cyclodextrin substituted with six hydroxypropyl groups (“DS-6”); wherein the mixture comprises less than 6 International Units (IU) of endotoxins per gram.
2 . The method of claim 1 , wherein the mixture comprises less than 3% unsubstituted beta-cyclodextrin (“DS-0”) and beta-cyclodextrin substituted with one hydroxypropyl group (“DS-1”), collectively.
3 . The method of claim 1 , wherein the mixture comprises less than 2% unsubstituted beta-cyclodextrin (“DS-0”) and beta-cyclodextrin substituted with one hydroxypropyl group (“DS-1”), collectively.
4 . The method of claim 1 , wherein the mixture comprises less than 1% unsubstituted beta-cyclodextrin (“DS-0”) and beta-cyclodextrin substituted with one hydroxypropyl group (“DS-1”), collectively.
5 . The method of claim 1 , wherein the mixture comprises less than 2% unsubstituted beta-cyclodextrin (“DS-0”).
6 . The method of claim 1 , wherein the mixture comprises less than 1% unsubstituted beta-cyclodextrin (“DS-0”).
7 . The method of claim 1 , wherein the mixture comprises less than 1% beta-cyclodextrin substituted with nine hydroxypropyl groups (“DS-9”) and beta-cyclodextrin substituted with ten hydroxypropyl groups (“DS-10”), collectively.
8 . The method of claim 1 , wherein administering comprises intrathecal or intravenous injection.
9 . The method of claim 1 , wherein administering comprises intracerebroventricular injection.
10 . The method of claim 1 , wherein the mixture comprises less than 5 International Units (I) of endotoxins per gram.
11 . The method of claim 1 , wherein the mixture comprises less than 2 International Units (I) of endotoxins per gram.
12 . The method of claim 1 , wherein the mixture comprises less than 1 International Units (IU) of endotoxins per gram.
13 . The method of claim 1 , wherein the mixture comprises less than 0.5 International Units (I) of endotoxins per gram.
14 . The method of claim 1 , wherein the mixture comprises less than 0.3 International Units (I) of endotoxins per gram.
15 . The method of claim 1 , wherein the mixture comprises less than 0.2 International Units (I) of endotoxins per gram.
16 . The method of claim 1 , wherein the mixture comprises less than 0.1 International Units (I) of endotoxins per gram.
17 . The method of claim 1 , wherein the mixture comprises less than 0.05 International Units (I) of endotoxins per gram.
18 . The method of claim 1 , wherein the mixture has an average number of hydroxypropyl groups per beta-cyclodextrin (“DSa”) from about 3 to about 7.
19 . The method of claim 1 , wherein the mixture has an average number of hydroxypropyl groups per beta-cyclodextrin (“DSa”) in the range of about 4.06-4.76.
20 . The method of claim 1 , wherein the mixture has an average number of hydroxypropyl groups per beta-cyclodextrin (“DSa”) in the range of about 4.6-4.7.
21 . The method of claim 1 , wherein the mixture has an average number of hydroxypropyl groups per beta-cyclodextrin (“DSa”) in the range of 4.2±0.3.
22 . The method of claim 1 , wherein the mixture has an average number of hydroxypropyl groups per beta-cyclodextrin (“DSa”) in the range of 4.3±0.3.
23 . The method of claim 1 , wherein the mixture has an average number of hydroxypropyl groups per beta-cyclodextrin (“DSa”) in the range of 4.7±0.3.
24 . The method of claim 1 , wherein the mixture has an average number of hydroxypropyl groups per beta-cyclodextrin (“DSa”) in the range of 4.8±0.3.
25 . A method for treating Niemann Pick disease comprising administering to a human subject in need thereof a mixture of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, the mixture comprises beta-cyclodextrin substituted with three hydroxypropyl groups (“DS-3”), beta-cyclodextrin substituted with four hydroxypropyl groups (“DS-4”), beta-cyclodextrin substituted with five hydroxypropyl groups (“DS-5”), and beta-cyclodextrin substituted with six hydroxypropyl groups (“DS-6”), wherein the mixture has an average number of hydroxypropyl groups per beta-cyclodextrin (“DSa”) in the range of about 4.06-4.76; wherein the mixture comprises less than 6 International Units (IU) of endotoxins per gram.
26 . The method of claim 25 , wherein the mixture comprises more than 0.5% propylene glycol.
27 . The method of claim 25 , wherein the mixture comprises no more than 1 ppm propylene oxide.
28 . The method of claim 25 , wherein the mixture comprises less than 5 International Units (IU) of endotoxins per gram.